---
title: "Varegacestat (AL102) in Desmoid tumors: Access and distribution"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Access and distribution. Topics: Planned U.S. commercialization through an internal commercial organization; Launch focus on sarcoma centers of excellence; Distribution, supply chain, and commercial supply; Market access and patient support planning; 2 further topics. 6 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/access-and-distribution"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Planned U.S. commercialization through an internal commercial organization

> “In the United States, we expect to commercialize the product through a focused internal commercial organization, which would include capabilities in marketing, analytics, market access, and a targeted sales force designed to reach specialized treatment centers.”
> “Outside of the United States, we anticipate pursuing a flexible commercialization strategy. In certain key markets, including Europe, we may retain commercial rights and build a focused internal commercial team to support commercialization activities, subject to obtaining marketing approvals.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.11-2"></a>

### Launch focus on sarcoma centers of excellence

> “~85 Sarcoma Centers-of-Excellence”
> “Efficiently expand reach across the community through treatment center growth”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

> “Launch focused on 85 sarcoma centers of excellence expected to drive efficiency and quick uptake”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-2.1.2.11-3"></a>

### Distribution, supply chain, and commercial supply

> “Distribution & supply chain leverages prior oncology launches”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

> “We are also making investments intended to support commercial supply readiness for varegacestat.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

### Market access and patient support planning

> “early market access planning intended to support appropriate patient access; and a build-out of patient support capabilities aligned with the chronic nature of treatment in this population”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

> “>90% anticipated payer coverage”
> “US & EMA orphan designation has favorable pricing implications”

Source: [Immunome topline call presentation (2025)](https://investors.immunome.com/wp-content/uploads/2025/12/Immunome-Topline-Call-Presentation-FINAL.pdf)

<a id="topic-2.1.2.11-5"></a>

### Treatment duration expected in practice

> “Patients may receive ~1.5–2 years of treatment, pause, and return for treatment”

Source: [Immunome corporate presentation, October 2026 (2026)](https://investors.immunome.com/wp-content/uploads/2026/10/Immunome-Investor-Presentation-October-2026.pdf)

<a id="topic-2.1.2.11-6"></a>

### Expanded access before approval

> “Immunome is not making our investigational therapies available via expanded access at this time. We believe that participation in our clinical trials will be the most appropriate way to access our investigational therapies prior to their approval.”

Source: [Immunome expanded access policy](https://immunome.com/patients/)

<a id="topic-2.1.2.11-7"></a>

### Specialty pharmacy or specialty distributor arrangements

No evidence found.

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
